Effects of fluoxetine on fish: What do we know and where should we focus our efforts in the future?

被引:23
|
作者
Correia, Daniela [1 ]
Domingues, Ines [1 ]
Faria, Melissa [2 ]
Oliveira, Miguel [1 ]
机构
[1] Univ Aveiro, Ctr Environm & Marine Studies CESAM, Dept Biol, Campus Univ Santiago, P-3810193 Aveiro, Portugal
[2] IDAEA CSIC, Jordi Girona 18, Barcelona 08034, Spain
关键词
SSRIs; Antidepressants; Serotonin; Effects; Environmental levels; SEROTONIN REUPTAKE INHIBITORS; ZEBRAFISH DANIO-RERIO; PHARMACEUTICAL POLLUTANT FLUOXETINE; SOLID-PHASE EXTRACTION; ENVIRONMENTALLY-RELEVANT CONCENTRATIONS; WASTE-WATER CONTAMINANTS; TRAP MASS-SPECTROMETRY; PERSONAL CARE PRODUCTS; SIAMESE FIGHTING FISH; ANTIDEPRESSANT FLUOXETINE;
D O I
10.1016/j.scitotenv.2022.159486
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Fluoxetine is one of the most studied and detected selective serotonin reuptake inhibitors in the aquatic environment, found at concentrations ranging from ng/L to mu g/L. Its presence in this environment can induce effects on aquatic or-ganisms that may compromise their fitness. Several experimental studies have demonstrated that fluoxetine can in-duce neurotoxicity, genetic and biochemical changes, and cause behavioral dysfunction in a wide range of fish species. However, contradictory results can be found. There is thus the need for a comprehensive review of the current state of knowledge on the effects of fluoxetine on fish at different levels of biological organization, highlighting inclu-sive patterns and discussing the potential causes for the contradictory results, that can be found in the available liter-ature. This review also aims to explore and identify the main gaps in knowledge and areas for future research. We conclude that environmentally relevant concentrations of fluoxetine (e.g., from 0.00345 mu g/L) produced adverse ef-fects and often this concentration range is not addressed in conventional environmental risk assessment strategies. Its environmental persistence and ionizable properties reinforce the need for standardized testing with representative aquatic models, targeting endpoints sensitive to the specific mode of action of fluoxetine, in order to assess and rank its actual environmental risk to aquatic ecosystems.
引用
收藏
页数:19
相关论文
共 50 条
  • [41] Diabetes and Screening for Coronary Heart Disease: Where Should We Focus our Efforts?
    Maria de la Hera, Jesus
    Manuel Garcia-Ruiz, Jose
    Delgado, Elias
    REVISTA ESPANOLA DE CARDIOLOGIA, 2015, 68 (10): : 830 - 833
  • [42] Psychopharmacologic interventions in nursing homes: What do we know and where should we go?
    Ryan, JM
    Kidder, SW
    Daiello, LA
    Tariot, PN
    PSYCHIATRIC SERVICES, 2002, 53 (11) : 1407 - 1413
  • [43] Cardiac troponin release in athletes: what do we know and where should we go?
    Janssen, Sylvan L. J. E.
    Berge, Kristian
    Luiken, Tom
    Aengevaeren, Vincent L.
    Eijsvogels, Thijs M. H.
    CURRENT OPINION IN PHYSIOLOGY, 2023, 31
  • [44] Electronic shopping cart abandonment: What do we know and where should we be heading?
    Chopra, Ishani Patharia
    Jebarajakirthy, Charles
    Jain, Tanu
    Maseeh, Haroon Iqbal
    ELECTRONIC MARKETS, 2024, 34 (01)
  • [45] Alcohol, the heart and the cardiovascular system: What do we know and where should we go?
    Rehm, Juergen
    Roerecke, Michael
    DRUG AND ALCOHOL REVIEW, 2011, 30 (04) : 335 - 337
  • [47] Positive Affect and Health: What Do We Know and Where Next Should We Go?
    Pressman, Sarah D.
    Jenkins, Brooke N.
    Moskowitz, Judith T.
    ANNUAL REVIEW OF PSYCHOLOGY, VOL 70, 2019, 70 : 627 - 650
  • [48] Alcohol consumption and mortality. What do we know and where should we go?
    Rehm, J
    ADDICTION, 2000, 95 (07) : 989 - 995
  • [49] Social Policy and the Achievement Gap: What Do We Know? Where Should We Head?
    Bower, Corey Bunje
    EDUCATION AND URBAN SOCIETY, 2013, 45 (01) : 3 - 36
  • [50] Breast cancer risk reduction: What do we know and where should we go?
    Prout, MN
    MEDSCAPE WOMENS HEALTH, 2000, 5 (05):